The study found that these claims were more common in US states that listed opioid use disorder as a qualifying condition for medical cannabis.
To help decide what to do with the impounded products, state authorities are welcoming input from the public until July 15.
David Hardstaff of BCL Solicitors LLP discuss the issues surrounding legal access to medical cannabis in the UK, as outlined in a recent in-depth report.
Product testing conducted by the US Food and Drug Administration (FDA) has found that many CBD-infused products on sale in the United States are mislabeled, containing vastly differing amounts of CBD than advertised on the product packaging.
The new rule was initially meant to take effect on April 1, but delays were made amid the coronavirus pandemic.